Benign Prostatic Hyperplasia

There were also no reports of sexual dysfunction related to device or procedure and no reported cases of sustained de novo erectile dysfunction at 5 years.

The Optilume drug-coated balloon catheter system is used to treat patients with lower urinary tract symptoms related to benign prostatic hyperplasia.

"Placing a catheter to irrigate obstructing blood clots (CPT 51700) is specifically included in the payment for the TURP if this complication is managed outside of an operating room," write Jonathan Rubenstein, MD, and Mark Painter.

Medical necessity must be documented on the chart in order to bill code.

“The take-home message is that for the appropriate patient, each of [these] technologies works well,” says Richard K. Lee, MD, MBA.

A procedural code is now available to hospitals in France enabling use of UroLift to treat men aged ≥50 years with symptoms of an enlarged prostate up to 100 cc.

The highest risk was observed in patients exposed to alpha blocker therapy alone.

Tadfin is a once-daily capsule that combines 5 mg of tadalafil (Cialis) with 5 mg of finasteride (Proscar).

The investigators also determined independent factors affecting the efficacy of vibegron in this setting.

The XFLO Expander System provided patients with symptom relief while preserving sexual function.

The risks of erectile dysfunction or rectourethral fistula post-cryosurgery were also not increased by prior surgical interventional therapy for benign prostatic hyperplasia.

Investigators reported that the treatment-emergent adverse event results showed combination tamsulosin and mirabegron was well-tolerated and had a favorable safety profile.

Holmium laser lithotripsy with Moses 2.0 is intended to enhance precision and versatility by optimizing laser energy transmission.

The drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.

Minimally invasive water vapor thermal therapy offers rapid improvements in LUTS, QoL, and flow rate that remain durable to 5 years in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

The study compared the 2 procedures over 24 months of follow-up.

Significant improvements in BPH-related lower urinary tract symptoms were observed with the system.

Steven A. Kaplan, MD, explains the updates in the AUA 2020 guideline on lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Only 1.5% of patients undergo repeat surgical intervention for BPH recurrence.

Patient-reported outcomes showed a superior experience regarding post-procedure BPH symptoms with the UroLift prostatic urethral lift over Rezum tissue ablation with steam injection.